Skip to main content

In a world increasingly focused on people’s health, the pharmaceutical industry plays a key role in providing effective and safe medicines. The core of the pharmaceutical production relies on the Active Pharmaceutical Ingredients (APIs), which are the essential components responsible for the therapeutic action of the drugs.

These substances have specific pharmacological properties that enable drugs to fulfill their therapeutic function. To produce them with maximum quality guarantees, it is important to have high-tech industrial methodologies and processes, as well as to comply with good manufacturing practice (GMP) regulations, both in development stage and during commercial production.

In this article, we will analyze the current trends in the pharmaceutical sector related to APIs and their production, what challenges they entail and what the keys to address them are.

 

Main properties of APIs

During their life cycle, the APIs are evaluated and selected for their ability to interact with biological systems and provide the desired effect. Their therapeutic activity can encompass a wide range of functions, such as inhibiting viral replication, regulating immune response or modulating enzyme activity.

In addition, they are designed to target specific processes in the body, allowing them to interact selectively with receptors on the affected cells or tissues, thus minimizing unwanted side effects.

While it is true that the active pharmaceutical ingredients market has traditionally been dominated by certain widely used drugs, demand is now increasingly shifting towards the development of more complex APIs for more targeted therapies. A trend consistent, in fact, with the implementation of increasingly personalized medicine.

One of the consequences of this specificity is that the target population for drugs tends to shrink, as do therapeutic doses and the annual demand for APIs. But, in parallel, the availability of different APIs is increasing. Ultimately, the goal is to achieve more effective treatments for more complex and rare conditions.

At AGC Pharma Chemicals, we know that it is essential for a CDMO to be at the forefront of API development. If you are seeking solutions to the challenges presented by these trends, we invite you to get in touch with our team of experts. We are prepared to offer you comprehensive information about our advanced technologies, industrial processes, and how we can assist you in accomplishing your goals. Find out how AGC Pharma Chemicals can be your trusted partner in the production of quality API’s.

Latest News

Events & ConventionsAGC Pharma Chemicals at BOS Manchester 2024
12th November 2024

AGC Pharma Chemicals at BOS Manchester 2024

We are thrilled to announce our participation in BOS (Biotech Outsourcing Strategies) Manchester 2024, November 26-27.   BOS Manchester 2024's scope is primarily development stage CMC outsourcing for both Small Molecules…
Supply ChainAGC Pharma Chemicals Joins the Pharmaceutical Supply Chain Initiative as a Supplier Partner
6th November 2024

AGC Pharma Chemicals Joins the Pharmaceutical Supply Chain Initiative as a Supplier Partner

AGC Pharma Chemicals, a global contract development and manufacturing organization (CDMO) specializing in small-molecule APIs and intermediates, is proud to announce its new partnership with the Pharmaceutical Supply Chain Initiative…
Events & ConventionsAGC Pharma Chemicals at Bio Europe Stockholm 2024
1th November 2024

AGC Pharma Chemicals at Bio Europe Stockholm 2024

We are excited to be attending Bio Europe 2024 in Stockholm from November 4-6. Our team, represented by Business Development Associate Directors Monica Delgado and João Madeira do Ó, will…